On Trial10 Jun 20262 MIN

I tested fillers but without a needle

The Ordinary’s Volufiline serum promises plump, bouncy skin—no appointment required. One month in, here’s what actually happened

The Ordinary Volufiline

Artwork by The Nod

Somewhere in my early thirties, my under-eyes decided to start keeping score—deep-set, slightly hollow, the kind that make you look tired on days you aren’t. And no amount of sleep or eye cream has worked. Needles aren't something I’m considering anytime soon, so when The Ordinary’s Volufiline started doing the rounds on TikTok—the key ingredient claims to do what fillers do, minus the part I wasn’t ready for—I’ll admit I was a bit intrigued.

What’s actually in this bottle

Volufiline is a patented ingredient developed by French cosmetics lab Sesderma, the same people behind Matrixyl-3000 (a peptide complex widely used in anti-ageing skincare). Its active compound is sarsasapogenin, derived from the root of Anemarrhena asphodeloides (known as zhi mu in traditional Chinese medicine and used for centuries to treat inflammation). Unlike hyaluronic acid, which draws water to the skin’s surface, sarsasapogenin works deeper—it activates a receptor pathway called PPARγ, essentially a master switch for fat cell maturation, prompting immature fat cells to develop and store more lipid. In theory: fuller-looking skin from underneath.

Originally applied to the chest area for volume and firmness (yes, really), it was repackaged by Korean beauty brands as a topical alternative to injectable fillers. The Ordinary’s version—a 15ml bottle at a fraction of what a filler appointment would cost—pairs 92 per cent Volufiline with 1 per cent Pal-Isoleucine (a peptide that supports collagen and skin resilience). The internet calls it “filler in a bottle”. My expectations were measured, at best. 

The beauty desk made me do it

I’ll be honest: I assumed gimmick. Another trend capitalising on insecurities, dressed up in credible-sounding science. Still, it had landed on the beauty desk, and ignoring something that’s sitting right in front of you requires more discipline than I have. The texture is slightly viscous, oil-like, but the good part is, it absorbs fast, and my moisturiser went on smoothly on top. A little goes a long way with this one.

What a month of consistent use actually looks like

Days two and three: my under-eyes felt more hydrated. Nothing dramatic—no one was stopping me in the street. After a consistent month, though, there was a visible difference: my under-eyes looked brighter and slightly fuller, and my smile lines, while not gone, were softer. My skin had a bounce to it that I’d been missing. The keyword throughout was consistency—this is not a product you can be casual with. Experts note that any plumping effect comes from the gradual accumulation of fat cell activity, which means it kicks in slowly and fades just as slowly once you stop. It’s a long-term commitment, not an instant fix. To see a more significant change, I’d recommend a minimum of two to three months of daily use, targeted precisely at the areas you care about.

Worth the vanity real estate?

Can it replace an in-office injectable? No. A dermatologist will rightly point out that topicals don’t reliably reach the deeper structural layers where real volume loss happens. This works as a soft, surface-level enhancement, not the architectural shift a filler delivers. The results are also maintenance-dependent: stop using it, and they gradually reverse. But as a skincare-drawer staple that quietly does something? It earns its keep. It evens, plumps, and gives skin a healthier, fuller appearance with consistent use. And, at this price point, that’s not nothing. Consider it a filler’s younger, less invasive cousin: subtle, effective within its limits, and significantly less commitment.

The Ordinary Volufiline 92% + Pal-Isoleucine 1% Targeted Plumping Serum (15 ml) is available online for ₹1,700

—As told to Nandini Gulati

The Nod Newsletter

We're making your inbox interesting. Enter your email to get our best reads and exclusive insights from our editors delivered directly to you.